Salarius Pharmaceuticals Inc (SLRX NASDAQ) stock market data APIs
$0.7348
-0.05(-6.8%)
as of May 6, 2025
Salarius Pharmaceuticals Inc Financial Data Overview
Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is based in Houston, Texas.
Prev. Close
0.7348
Open
0.687
High
0.743
Low
0.6838
52 wk Range
0.4519-4.5
Market Cap
1 468 K
Shares Outstanding
2 127 K
EPS
-0.76
Beta
0.416
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Salarius Pharmaceuticals Inc data using free add-ons & libraries
Get Salarius Pharmaceuticals Inc Fundamental Data
Salarius Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -5 729 892
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: -53.6
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Salarius Pharmaceuticals Inc News
New
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide c...
Wondering what's happening in today's after-hours session?
Enable social media cookies to share Wondering what's happening in today's after-hours session? By Mill Chart Last update: Apr 8, 2025 Let's have a look at what is happening on the US markets afte...
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update
Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating resp...
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and have not progressed after at least 14.5, 19.7 and 22.8...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
